Guselkumab ‘boosts response’ in resistant psoriatic arthritis
The COSMOS trial shows the therapy is effective in patients who have failed an anti-TNF, researchers report
The IL-23 inhibitor guselkumab is more effective than placebo in patients with psoriatic arthritis who are resistant to tumour necrosis factor inhibitors, a phase III trial shows.
“Guselkumab is a relatively new treatment and is the first drug in its class to gain approval for psoriatic arthritis (PsA),” says study lead author, Dr Laura Coates of the University of Oxford, UK.
“Previous studies — the DISCOVER trials — showed that it was effective for peripheral musculoskeletal disease (arthritis, enthesitis, dactylitis) in addition to known efficacy in skin/nail psoriasis from dermatology studies.”
Most patients in these trials were receiving guselkumab as their first biologic, she noted.
